Observations placeholder

Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade names Campath, MabCampath and Campath-1H, and in the treatment of multiple sclerosis as Lemtrada. It is also used in some conditioning regimens for bone marrow transplantation, kidney transplantation and islet cell transplantation.

(Mab)Campath was withdrawn from the markets in the US and Europe in 2012 to prepare for a higher-priced relaunch of Lemtrada aimed at multiple sclerosis.

A complication of therapy with alemtuzumab is that it significantly increases the risk for opportunistic infections, in particular, reactivation of cytomegalovirus.

On Oct, 8, 2015: 3,765 people reported to have side effects when taking Campath. Among them, 13 people (0.35%) have Hallucinations.

On Sep, 30, 2015: 3,765 people reported to have side effects when taking Campath. Among them, 141 people (3.75%) have Death.

Time on Campath when people have Death  :

< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death54.55%45.45%0.00%0.00%0.00%0.00%0.00%